Stem definition | Drug id | CAS RN |
---|---|---|
humanized origin | 5409 | 1535963-91-7 |
Molecule | Description |
---|---|
Synonyms:
|
Satralizumab-mwge is a recombinant humanized anti-human interleukin 6 (IL-6) receptor monoclonal antibody based on a human IgG2 framework. It is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients. The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
|
None
None
Date | Agency | Company | Orphan |
---|---|---|---|
June 24, 2021 | EMA | Roche Registration GmbH | |
Aug. 14, 2020 | FDA | GENENTECH | |
June 29, 2020 | PMDA | Chugai Pharmaceutical Co., Ltd. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Urinary tract infection | 47.75 | 39.40 | 25 | 333 | 264659 | 63224005 |
Myelitis | 40.57 | 39.40 | 7 | 351 | 1396 | 63487268 |
None
None
None
Source | Code | Description |
---|---|---|
ATC | L04AC19 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Neuromyelitis optica | indication | 25044007 | DOID:8869 |
Tuberculosis | contraindication | 56717001 | |
Viral hepatitis type B | contraindication | 66071002 | DOID:2043 |
None
None
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Interleukin-6 receptor | Membrane receptor | ANTAGONIST | Kd | 8.82 | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
D11079 | KEGG_DRUG |
YB18NF020M | UNII |
C4726732 | UMLSCUI |
CHEMBL3833307 | ChEMBL_ID |
DB15762 | DRUGBANK_ID |
9093 | IUPHAR_LIGAND_ID |
018474 | NDDF |
897234001 | SNOMEDCT_US |
897291006 | SNOMEDCT_US |
4039644 | VANDF |
4039645 | VANDF |
2391541 | RXNORM |
337831 | MMSL |
38756 | MMSL |
d09618 | MMSL |
C000655944 | MESH_SUPPLEMENTAL_RECORD_UI |
10065 | INN_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Enspryng | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-007 | INJECTION, SOLUTION | 120 mg | SUBCUTANEOUS | BLA | 28 sections |
Enspryng | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-007 | INJECTION, SOLUTION | 120 mg | SUBCUTANEOUS | BLA | 28 sections |
Enspryng | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50242-007 | INJECTION, SOLUTION | 120 mg | SUBCUTANEOUS | BLA | 28 sections |